吉非替尼治疗晚期非小细胞肺癌的临床研究

Clinical Research of Gefitinib Treatment of Advanced Non-small cell Lung Cancer

目的探讨吉非替尼治疗晚期非小细胞肺癌的疗效及其安全性。方法采用吉非替尼治疗晚期非小细胞肺癌患者37例,评价其近期疗效和不良反应。结果 37例患者治疗1个月后总有效率为62.2%,总疾病控制率91.9%;出现不良反应包括:痤疮样皮疹48.6%,皮肤干燥32.4%,腹泻24.3%,恶心13.5%,丙氨酸氨基转移酶异常29.7%,甲沟炎2.7%,无间质性肺炎等严重并发症发生。结论吉非替尼治疗适用于治疗既往接受过化学治疗或不适于化疗的局部晚期或转移性非小细胞肺癌,其疗效确切,不良反应较轻。

Objective To investigate the therapeutic effect and safe of gefitinib on treating advanced non-small cell lung cancer.Methods 37 patients with advanced non-small cell lung cancer were treated by gefitinib,the short term effect and adverse reactions were evaluated.Results 37 patients after one month of treatment the total effective rate was 62.2%,the total disease control rate was 91.9%;adverse reactions included：acneform eruptions 48.6%,dry skin 32.4%,diarrhea 24.3%,nausea 13.5%,abnormal alanine aminotransferase 29.7%,paronychia 2.7%,no serious complications such as interstitial pneumonia occurred.Conclusion Gefitinib therapy is suitable for patients who has previously received chemotherapy or patients with local advanced or metastatic non-small cell lung cancer which is not suitable for chemotherapy,it has definite efficacy and less side effects.